Search results
Results from the WOW.Com Content Network
A large-scale study in Buenos Aires from December 29, 2020, to May 15, 2021, with 663,602 participants aged 60 and older who received Spunik V, the Oxford–AstraZeneca vaccine, or the Sinopharm BIBP vaccine observed an overall efficacy of 98% (95% CI, 95 – 99%) against COVID-19-related deaths. The study noted that the three vaccines showed a ...
Moderna has launched a trial of a vaccine to tackle the Beta variant or lineage B.1.351. [460] On 17 February 2021, Pfizer announced neutralization activity was reduced by two-thirds for this variant, while stating that no claims about the efficacy of the vaccine in preventing illness for this variant could yet be made. [461]
Pfizer and Moderna vaccines are both safe and have similar effectiveness at preventing COVID-19 illness. Clinical trial data when they were first released in December 2020 showed 95% efficacy for ...
Vaccine Initial effectiveness by severity of COVID-19 Study location Refs Asymptomatic Symptomatic Hospitalization Death Oxford–AstraZeneca
Russia was quick to develop its two-dose Sputnik V vaccine last year and has also deployed a one-shot Sputnik Light vaccine, both of which have it says demonstrated high efficacy in trials, but ...
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. Moderna Inc ...
On 29 June 2021, the director of the Gamaleya Institute, Denis Logunov, said that Sputnik V is about 90% effective against the Delta variant. [81] On July 21, researchers from PHE published a study finding that the Pfizer vaccine was 93.7% effective against symptomatic disease from Delta after 2 doses, while the Astrazeneca vaccine was 67% ...
Vaccines from AstraZeneca , Russia's Gamaleya Institute and Johnson & Johnson fight the coronavirus with another virus, leaving scientists concerned the shots may lose potency if annual ...